Lutetium-labelled peptides for therapy of neuroendocrine tumours
| Autor: | Eric P. Krenning, W. W. de Herder, E. I. van Vliet, Dirk Jan Kwekkeboom, Saima Khan, Jaap J.M. Teunissen, Boen Liong Kam |
|---|---|
| Přispěvatelé: | Radiology & Nuclear Medicine, Internal Medicine |
| Rok vydání: | 2012 |
| Předmět: |
Oncology
medicine.medical_specialty Nausea medicine.medical_treatment Octreotide Review Article Lutetium Neuroendocrine tumors Disease-Free Survival Somatostatin receptor chemistry.chemical_compound Neuroendocrine tumours Internal medicine Lu-Octreotate Organometallic Compounds medicine Humans Radiology Nuclear Medicine and imaging Receptors Somatostatin Radioisotopes Octreotate business.industry Radiotherapy Dosage General Medicine medicine.disease Radiation therapy Neuroendocrine Tumors Somatostatin chemistry Radiology Nuclear Medicine and imaging Radionuclide therapy Radiopharmaceuticals medicine.symptom Peptides Nuclear medicine business Peptide receptor radionuclide therapy (PRRT) medicine.drug |
| Zdroj: | European Journal of Nuclear Medicine and Molecular Imaging European Journal of Nuclear Medicine and Molecular Imaging, 39, 103-112. Springer-Verlag |
| ISSN: | 1619-7070 |
| Popis: | Treatment with radiolabelled somatostatin analogues is a promising new tool in the management of patients with inoperable or metastasized neuroendocrine tumours. Symptomatic improvement may occur with (177)Lu-labelled somatostatin analogues that have been used for peptide receptor radionuclide therapy (PRRT). The results obtained with (177)Lu-[DOTA(0),Tyr(3)]octreotate (DOTATATE) are very encouraging in terms of tumour regression. Dosimetry studies with (177)Lu-DOTATATE as well as the limited side effects with additional cycles of (177)Lu-DOTATATE suggest that more cycles of (177)Lu-DOTATATE can be safely given. Also, if kidney-protective agents are used, the side effects of this therapy are few and mild and less than those from the use of (90)Y-[DOTA(0),Tyr(3)]octreotide (DOTATOC). Besides objective tumour responses, the median progression-free survival is more than 40 months. The patients' self-assessed quality of life increases significantly after treatment with (177)Lu-DOTATATE. Lastly, compared to historical controls, there is a benefit in overall survival of several years from the time of diagnosis in patients treated with (177)Lu-DOTATATE. These findings compare favourably with the limited number of alternative therapeutic approaches. If more widespread use of PRRT can be guaranteed, such therapy may well become the therapy of first choice in patients with metastasized or inoperable neuroendocrine tumours. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|